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ORIGINAL ARTICLE
In 1989, Gerald and Rosai reported a distinctive
type of malignant small-cell tumor with a predilec-
tion for occurring in the abdominal cavity of young
males.1 Histologically, the tumor was characterized
by nests of small, blue round cells in a desmo-
plastic stroma, and was thus named desmoplastic
small round cell tumor (DSRCT). Differentiation
of DSRCT from other small round cell tumors is
important because of its highly aggressive nature,
with an average survival of less than 2 years.2
Immunohistochemical staining has been used to
differentiate DSRCT from other small round cell
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Background/Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare but highly aggressive tumor
that usually occurs in the abdominal cavity of young males. Immunohistochemical staining plays an 
important role in the differentiation of DSRCT from other small round cell neoplasms. Recently, a novel
translocation of chromosome 11 and 22 [t(11;22)(p13 + q12)] was identified in DSRCTs, which could result
in the formation of the chimeric EWS-WT1 fusion gene. Reverse transcriptase–polymerase chain reaction
(RT-PCR) has been applied to detect the fusion gene in fresh tissue and confirm the diagnosis. Only a few
studies using RT-PCR with formalin-fixed and paraffin-embedded (FFPE) tissue sections to detect the specific
transcript have been reported.
Methods: We collected four patients who had been diagnosed with DSRCT from the archives of the
Department of Pathology, National Taiwan University Hospital, between 1996 and 2006. The clinical in-
formation and histologic sections of the patients were reviewed. Panel of primary antibodies including cy-
tokeratin, vimentin, desmin and WT-1 were used for immunohistochemical staining. RNA extracted from
the FFPE tissue sections was used for RT-PCR to identify the transcript of EWS-WT1.
Results: All four patients were male, with a mean age of 24 years. All of the tumors originated in the abdom-
inal cavity and liver metastases were found in two patients. Two patients died of disease within 2 years, and
the other two remained alive with disease. Histologically, the tumors were composed of nests of primitive
small round cells within a desmoplastic stroma. Immunohistochemically, all the tumor cells were reactive
to cytokeratin, vimentin, desmin and WT-1. The characteristic EWS-WT1 fusion gene could be identified
in the FFPE specimens of all three patients who had tissue sections available for RT-PCR analysis.
Conclusion: DSRCT is an aggressive tumor that usually occurs in the peritoneum of young males. The
tumor is characterized by the expression of cytokeratin, vimentin, desmin and WT-1. RT-PCR, using paraffin-
embedded tissue sections, can effectively detect the characteristic EWS-WT1 fusion gene transcript. [J Formos
Med Assoc 2007;106(10):854–860]
Key Words: desmoplastic small round cell tumor, reverse transcriptase–polymerase chain reaction
©2007 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Department of Pathology, National Taiwan University Hospital, and 2National Taipei College of Nursing, Taipei, Taiwan.
Received: March 6, 2007
Revised: April 4, 2007
Accepted: July 3, 2007
*Correspondence to: Dr Cheng-Hsiang Hsiao, Department of Pathology, National Taiwan University Hospital,
7 Chung-Shan South Road, Taipei 100, Taiwan.
E-mail: chhsiao7@ntu.edu.tw
Clinicopathologic study of desmoplastic small round cell tumor
J Formos Med Assoc | 2007 • Vol 106 • No 10 855
neoplasms.2–4 In 1992, a novel reciprocal translo-
cation of chromosome 11 and 22 [t(11;22)(p13;
q12)] was identified in DSRCT.5 This transloca-
tion brings the EWS gene on chromosome 22 to
the WT1 gene on chromosome 11, resulting in an
EWS-WT1 fusion gene.6 The chimeric protein leads
to an overexpression of WT1 protein in the tumor
cells. This specific gene translocation in sarcomas
can be detected by various methods including
Southern blot, fluorescent in situ hybridization
(FISH) and reverse transcriptase–polymerase chain
reaction (RT-PCR).7–9 However, Southern blot
and FISH require fresh frozen tissue sections and
do not work well with paraffin-embedded tissues.
RT-PCR analysis has been shown to be a very
sensitive, specific and reproducible method for
the diagnosis of soft tissue sarcomas with gene
translocation. With improvements in the technique
of RNA extraction, RT-PCR can also be used with
formalin fixed and paraffin-embedded tissue sec-
tions.6 In this study, we reviewed the clinical, his-
tologic and immunohistochemical characteristics
of four patients with DSRCT diagnosed in a med-
ical center of northern Taiwan. The EWS-WT1
fusion gene was also analyzed using RT-PCR
analysis of paraffin-embedded tissue sections.
Materials and Methods
The data of four patients who were diagnosed with
DSRCT in the 10 years from 1996 to 2006 were
retrieved from the archives of the Department of
Pathology, National Taiwan University Hospital.
Clinical history, treatment and follow-up data were
obtained by chart review. Routine hematoxylin
and eosin staining of the tissue sections were re-
viewed. Formalin-fixed and paraffin-embedded
tissue blocks were available in three of the four
patients (cases 1, 2, 3). Immunohistochemical
staining was performed on tissue sections using
the avidin–biotin–peroxidase complex technique
on an automatic immunostainer (BenchMark;
Ventana Medical Systems Inc., Tucson, AZ, USA).
Primary antibodies against AE1/AE3, EMA,
desmin, vimentin, CD99, NSE and WT-1 were
used. The sources and dilutions of each antibody
are listed in Table 1.
RT-PCR was performed with RNA extracted
from two 10-µm paraffin-embedded tissue sec-
tions using the TRIzol kit (Invitrogen, Carlsbad,
CA, USA). For comparison, RNA extracted from
the fresh frozen tumor tissue of case 1 was also
analyzed. The double strand cDNA was synthe-
sized using the one-tube, two-enzyme Access RT-
PCR System (Promega, Madison, WI, USA) and the
specific primer (EWS exon 7) for the EWS-WT1
fusion gene. PCR analysis was performed using 
a forward primer (5-TCCTACAGCCAAGCTC-
CAAGT-3, EWS exon 7) and reverse primer (5-
ACCTTCGGTTCACAGTCCTTG-3, WT1 exon 8).
PCR was performed with the following cycle pro-
file: 95°C for 5 minutes, followed by 40 cycles at
94°C for 1 minute, 62°C for 1 minute, and 72°C
for 2 minutes. An extension at 72°C for 10 minutes
was added after the last cycle.
To verify the sequence, the amplified products
were purified by the PCR-M Clean Up System
Table 1. Sources and dilution titer of primary antibodies
Marker Primary antibody clone Source Dilution
Cytokeratin AE1 and AE3 Biogenex* 1:100
EMA E29 Dako† 1:100
Vimentin V9 Dako† 1:50
CD99 O13 Signet‡ 1:120
Desmin 33 Biogenex* 1:80
WT-1 WLM04 Neomarker§ 1:25
*Biogenex Laboratories, San Ramon, CA, USA; †Dako Corporation, Carpinteria, CA, USA; ‡Signet Laboratories, Dedham, MA, USA;
§Neomarker Lab Vision Corporation, Fremont, CA, USA.
Y.S. Lee, C.S. Hsiao
856 J Formos Med Assoc | 2007 • Vol 106 • No 10
(Viogene, Sunnyvale, CA, USA) and then analyzed
with the ABI Prism 3730 sequence detection system
(Applied Biosystems, Foster City, CA, USA) using
both 5 and 3 inside primers.
Results
Clinical features
The four patients were all male, with a mean age
of 24 years (range, 16–38 years). All patients had
the initial presentation of abdominal mass with
abdominal pain. Liver metastasis was documented
in two patients (cases 3 and 4) and bone marrow
biopsy was also performed in these two patients,
both with negative findings.
Debulking surgery with adjuvant chemother-
apy was performed in three of the patients (cases 1,
2, 3). Concurrent chemotherapy and radiotherapy
was given to one patient (case 4). The outcome of
treatment was poor, with two patients dying of
disease within 2 years after diagnosis (cases 3 and
4) and the other two had tumor recurrence, with
one of them having multiple recurrences over a
10-year follow-up period (case 2). The clinical
manifestations and site of involvement and treat-
ment of each patient are listed in Table 2.
Histologic features
Grossly, the tumors all formed a solid, large mul-
tilobulated mass with multiple satellite nodules
on the peritoneum. The cut surface of the tumor
was white and firm with focal cystic change
(Figure 1). Histologic examination showed that the
tumors were composed of nests of small round
cells surrounded by a prominent desmoplastic
stroma. The size of the tumor nests varied with
occasional central necrosis. Trabecular or Indian-
file arrangements were also seen. Cytologically,
the tumor cells had small hyperchromatic nuclei
with inconspicuous nucleoli, scant cytoplasm and
indistinct cell borders (Figure 2).
Immunohistochemical study revealed that the
tumor cells were reactive to cytokeratin (AE1/AE3)
in the cytoplasm and WT1 in the nucleus. In ad-
dition, the tumors of all four patients had a char-
acteristic paranuclear dot-like staining pattern of
desmin and vimentin. The tumor cells were also
positive for EMA but negative for CD99 (Figure 3).
RT-PCR analysis using the primers for EWS
exon 7 and WT1 exon 8 revealed a 103-bp prod-
uct in the three patients who had adequate tissue
Table 2. Clinical manifestations, site of involvement and treatment of patients with desmoplastic small round cell tumor
Case Age (yr)/Sex Clinical manifestations (size) Site of involvement Treatment Outcome
1 18/M Abdominal mass (22 cm), Abdominal cavity S + C Recurred in 11 mo after S
abdominal pain Alive, 18 mo
2 24/M Abdominal mass (10 cm) Abdominal cavity S + C Recurred 3 times
Alive, 10 yr
3 38/M Abdominal pain, weight loss, Abdominal cavity, multiple S + C DOD, 14 mo
bowel habit change hepatic tumors
4 16/M Abdominal distension with Liver, abdominal cavity, C + R DOD, 23 mo
dyspnea and hydronephrosis abdominal wall
S = surgery; C = chemotherapy; R = radiotherapy; DOD = died of disease.
Figure 1. The tumor is white and fibrotic with occasional
cystic change on cut surface.
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specimens for study (Figure 4). DNA sequence
analysis of the PCR product confirmed that the
chimeric transcripts were composed of an in-frame
junction of exon 7 of EWS to exon 8 of WT1. The
results of immunohistochemical and molecular
analyses are summarized in Table 3.
Discussion
DSRCT is a rare tumor that is composed of nests
of small rounds cells within a desmoplastic stroma.
Cytologically, it is difficult to differentiate from
other small round cell neoplasms such as primitive
A B
Figure 2. (A) Nest or trabecula of tumor cells in a desmoplastic stroma (hematoxylin & eosin, 100×). (B) Tumor cells have
vesicular round nuclei with inconspicuous nucleoli and scanty cytoplasm (hematoxylin & eosin, 400×).
A B
C D
Figure 3. Immunohistochemistry (ABC stain, 400×). (A) Cytoplasmic staining for cytokeratin. Paranuclear dot staining
for: (B) vimentin; (C) desmin. (D) Nuclear staining for WT-1 is also present in the tumor cells.
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neuroectodermal tumor/Ewing’s sarcoma, small
cell carcinoma, neuroblastoma, Wilms’ tumor,
lymphoma and rhabdomyosarcoma.1 Immuno-
histochemical study is helpful for the diagnosis
of DSRCT. Unlike other small round cell neo-
plasms, DSRCTs express both epithelial and 
mesenchymal markers on immunohistochemi-
cal staining. In addition, DSRCTs usually show 
a dot-like staining pattern of desmin and vi-
mentin.1–3 The tumors of the four patients in this
study fulfilled the above criteria. All the tumor
cells were immunoreactive to cytokeratin and they
also showed the characteristic paranuclear dot-like
staining pattern of desmin and vimentin.
The exact nature of DSRCT remains uncertain.
Some have speculated that it is derived from
mesothelial or submesothelial cells, given the
predominant location of this tumor in mesothe-
lial cell-lined cavities and the immunohistochem-
ical expression of both epithelial and mesenchymal
antigens.6–10 Further support for this hypothesis
comes from the finding that the cells of DSRCT
invariably express desmin, as do normal meso-
thelial cells, submesothelial mesenchymal cells,
and some malignant mesothelioma.10 In addi-
tion, DSRCTs usually express WT1 protein, a tumor
marker that is also expressed in the serosal lining
epithelium of the fetus. These observations all
suggest that DSRCTs most likely arise from meso-
thelial or submesothelial cells.10 However, there
are some differences between the cells of DSRCTs
and mesothelial cells. First, DSRCTs usually ex-
press MOC-31, Ber-EP4 and Leu-M1, but the meso-
thelioma does not. Second, DSRCTs do not react
to cytokeratin 5/6 and thrombomodulin, but the
mesothelioma does.10 Third, there is no ultra-
structural evidence of mesothelial differentiation
in DSRCTs.10 Therefore, further study to establish
the origin of DSRCTs is needed.
Clinically, DSRCT is a highly aggressive neo-
plasm and complete excision is often impossible
because of the presence of multiple implants in
the peritoneum. The prognosis of DSRCT is ex-
tremely poor and the average survival is less than
2 years.2–4 Ordonez et al reported that 16 of 22
patients died of the disease within 8–50 months
after initial therapy.11 Another study of 35 pa-
tients with follow-up information found that 25
died of widespread metastasis, and the remain-
der were alive with disease at a mean duration of
25.2 months.4 Although the prognosis of DSRCT
is dismal, improved survival is possible with ex-
tensive surgical debulking followed by multimo-
dality therapy.12 In a study at the Memorial Sloan
Kettering Cancer center, 13 of 32 patients treated
with an extensive debulking procedure and sys-
temic chemotherapy remained progression-free
Figure 4. Reverse transcriptase–polymerase chain reac-
tion shows that the EWS-WT1 fusion gene is present in 
the specimens. (M = marker lane; N = negative control;
Lane 1 = fresh frozen specimen of case 1; Lanes 2, 3,
4 = formalin-fixed and paraffin-embedded specimens of
cases 2, 3 and 1 respectively).
300
200
100
M N 1 2 3 4
103 bp
Table 3. Results of immunohistochemical and molecular studies
Case Cytokeratin EMA NSE CD99 WT-1 Vimentin Desmin* RT-PCR
1 + + + − + + + +
2 + + − − + + + +
3 + + NA − + + + +
4 + NA + NA + NA + NA
*Dot-like staining pattern. NA = not available.
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for 3 years.12,13 In the present series, the outcome
was also poor. Two patients died of disease within
2 years (cases 3 and 4) and two patients remained
alive with disease.
In 1992, Sawyer et al identified a novel trans-
location of t(11;22)(p13;q12) in DSRCT.5 This
reciprocal translocation was confirmed to be 
a consistent feature of DSRCT by other investiga-
tors.6–9 Sequence analysis revealed that the trans-
location leads to the fusion of exon 7 of Ewing’s
sarcoma gene EWS on chromosome 22 with
exon 8 of Wilms’ tumor suppressor gene WT1 on
chromosome 11. Rare variants including additional
exons of EWS can occur.14 The resulting fusion
protein couples the EWS activation domain to
the WT1 zinc-finger DNA binding domain. The
chimeric protein can be detected with the WT1
(C19) antibody directed to the carboxyl termi-
nus of WT1 but cannot be detected with the WT1
antibody directed to the amino terminus of WT1.
The WTI protein is a transcriptional activator of
genes involved in renal and gonadal differentia-
tion. It regulates the mesenchymal to epithelial
transition that occurs in kidney development.15
Therefore, the overexpression of WT1 protein in
DSRCT may be associated with the expression of
both epithelial and mesenchymal markers in the
tumor cells. Recently, the EWS-WT1 fusion pro-
tein has been shown to be able to transcription-
ally activate insulin-like growth factor 1.16 Thus,
the EWS-WT1 fusion protein could promote the
proliferation of DSRCT cells through this mecha-
nism. The unique, consistent translocation in
DSRCT facilitates the development of RT-PCR di-
agnostic assays. PCR-based assays have been shown
to accurately detect EWS-WT1 fusion mRNA in
fresh tumor tissue of DSRCT.7 With improvements
in molecular biology, some studies report that
RT-PCR diagnostic assay can also be used with
paraffin-embedded tissue sections.6 In this series,
the EWS-WT1 fusion gene was detected using RT-
PCR in all three patients with available paraffin-
embedded tissue. Therefore, detection of the
EWS-WT1 fusion gene and chimeric transcript can
serve as a sensitive and specific marker for the 
diagnosis of DSRCT.
In summary, this series of four patients con-
firmed the young male predominance of DSRCT
and the aggressive nature of this disease. Immuno-
histochemically, DSRCT is characterized by the
expression of cytokeratin, vimentin, desmin and
WT1. RT-PCR analysis of the EWS-WT1 fusion
gene transcript can be successfully performed
with paraffin-embedded tissues to confirm the
diagnosis.
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